PARATEK PHARMACEUTICALS INC's ticker is PRTK and the CUSIP is 699374302. A total of 113 filers reported holding PARATEK PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.93 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,520,000 | +4.5% | 470,150 | 0.0% | 0.03% | -8.6% |
| Q4 2018 | $2,412,000 | -51.1% | 470,150 | -7.5% | 0.04% | -44.4% |
| Q3 2018 | $4,930,000 | -9.9% | 508,282 | -5.2% | 0.06% | -17.1% |
| Q2 2018 | $5,469,000 | -15.6% | 536,128 | +7.6% | 0.08% | -23.2% |
| Q1 2018 | $6,477,000 | -41.2% | 498,253 | -19.0% | 0.10% | -37.7% |
| Q4 2017 | $11,007,000 | -32.0% | 614,900 | -4.7% | 0.16% | -30.9% |
| Q3 2017 | $16,192,000 | +52.9% | 645,100 | +46.8% | 0.23% | +42.9% |
| Q2 2017 | $10,590,000 | +587.7% | 439,400 | +449.2% | 0.16% | +519.2% |
| Q1 2017 | $1,540,000 | – | 80,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 2,600,410 | $33,805,000 | 33.22% |
| Abingworth LLP | 1,041,131 | $13,535,000 | 8.41% |
| Roumell Asset Management, LLC | 197,347 | $2,566,000 | 5.65% |
| Trellus Management Company, LLC | 89,700 | $1,166,000 | 2.12% |
| Prosight Management, LP | 148,682 | $1,933,000 | 1.21% |
| Broadfin Capital, LLC | 477,607 | $6,209,000 | 0.97% |
| HIGHLAND CAPITAL MANAGEMENT LP | 959,278 | $12,471,000 | 0.64% |
| ARMISTICE CAPITAL, LLC | 580,000 | $7,540,000 | 0.58% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,500 | $1,346,000 | 0.52% |
| Opus Point Partners Management, LLC | 20,000 | $260,000 | 0.51% |